Monte Rosa will remain responsible for completion of the ongoing Phase 1 clinical study of MRT-6160 and is also eligible to ...
Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results